Disclosed herein is a substituted benzoylamino-indan-2carboxylic acid compounds of formula Ia wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and the use of the compounds or compositions thereof having the ability to block the CXCR5 receptor and inhibit B cell function associated with receptor activation and as such are useful in the treatment of inflammatory diseases, in particular rheumatoid arthritis, asthma, multiple sclerosis, lupus and Crohns disease.
